vs
ASP Isotopes Inc.（ASPI）与DELCATH SYSTEMS, INC.（DCTH）财务数据对比。点击上方公司名可切换其他公司
DELCATH SYSTEMS, INC.的季度营收约是ASP Isotopes Inc.的1.2倍（$20.7M vs $16.7M），ASP Isotopes Inc.同比增速更快（1295.7% vs 37.3%），DELCATH SYSTEMS, INC.自由现金流更多（$7.7M vs $-47.4M）
ASP Isotopes Inc.是一家特种材料企业，专注于高纯度定制同位素的研发与生产，产品广泛应用于核医学、靶向抗癌治疗、清洁能源及工业研究等领域，客户覆盖北美、欧洲及亚太地区。
德尔卡斯系统公司是一家上市特种医药与医疗器械企业，主打研发经皮灌注技术，该技术可将高剂量化疗药物精准递送至人体特定器官或病变区域。公司总部位于纽约州昆斯伯里，在全球拥有28项专利的知识产权组合，其核心产品经皮肝灌注技术目前正针对肿瘤开展二期和三期临床试验。
ASPI vs DCTH — 直观对比
营收规模更大
DCTH
是对方的1.2倍
$16.7M
营收增速更快
ASPI
高出1258.4%
37.3%
自由现金流更多
DCTH
多$55.1M
$-47.4M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.7M | $20.7M |
| 净利润 | — | $-1.9M |
| 毛利率 | 12.5% | 85.5% |
| 营业利润率 | — | -10.5% |
| 净利率 | — | -9.1% |
| 营收同比 | 1295.7% | 37.3% |
| 净利润同比 | -586.8% | 44.2% |
| 每股收益（稀释后） | — | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPIDCTH
| Q4 25 | $16.7M | $20.7M | ||
| Q3 25 | $4.9M | $20.6M | ||
| Q2 25 | — | $24.2M | ||
| Q1 25 | — | $19.8M | ||
| Q4 24 | — | $15.1M | ||
| Q3 24 | — | $11.2M | ||
| Q2 24 | — | $7.8M | ||
| Q1 24 | — | $3.1M |
净利润ASPIDCTH
| Q4 25 | — | $-1.9M | ||
| Q3 25 | $-12.9M | $830.0K | ||
| Q2 25 | — | $2.7M | ||
| Q1 25 | — | $1.1M | ||
| Q4 24 | — | $-3.4M | ||
| Q3 24 | — | $1.9M | ||
| Q2 24 | — | $-13.7M | ||
| Q1 24 | — | $-11.1M |
毛利率ASPIDCTH
| Q4 25 | 12.5% | 85.5% | ||
| Q3 25 | 8.7% | 87.2% | ||
| Q2 25 | — | 86.3% | ||
| Q1 25 | — | 85.6% | ||
| Q4 24 | — | 85.9% | ||
| Q3 24 | — | 85.4% | ||
| Q2 24 | — | 80.4% | ||
| Q1 24 | — | 71.2% |
营业利润率ASPIDCTH
| Q4 25 | — | -10.5% | ||
| Q3 25 | -306.1% | -1.9% | ||
| Q2 25 | — | 10.7% | ||
| Q1 25 | — | 3.2% | ||
| Q4 24 | — | 20.1% | ||
| Q3 24 | — | -11.2% | ||
| Q2 24 | — | -50.4% | ||
| Q1 24 | — | -327.4% |
净利率ASPIDCTH
| Q4 25 | — | -9.1% | ||
| Q3 25 | -263.7% | 4.0% | ||
| Q2 25 | — | 11.2% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | — | -22.5% | ||
| Q3 24 | — | 16.6% | ||
| Q2 24 | — | -176.9% | ||
| Q1 24 | — | -354.0% |
每股收益（稀释后）ASPIDCTH
| Q4 25 | — | $-0.05 | ||
| Q3 25 | $-0.15 | $0.02 | ||
| Q2 25 | — | $0.07 | ||
| Q1 25 | — | $0.03 | ||
| Q4 24 | — | $-0.06 | ||
| Q3 24 | — | $0.06 | ||
| Q2 24 | — | $-0.48 | ||
| Q1 24 | — | $-0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $333.3M | $43.5M |
| 总债务越低越好 | $14.4M | — |
| 股东权益账面价值 | $204.2M | $111.2M |
| 总资产 | $498.0M | $123.6M |
| 负债/权益比越低杠杆越低 | 0.07× | — |
8季度趋势，按日历期对齐
现金及短期投资ASPIDCTH
| Q4 25 | $333.3M | $43.5M | ||
| Q3 25 | $113.9M | $41.8M | ||
| Q2 25 | — | $34.4M | ||
| Q1 25 | — | $12.8M | ||
| Q4 24 | — | $32.4M | ||
| Q3 24 | — | $8.3M | ||
| Q2 24 | — | $14.8M | ||
| Q1 24 | — | $11.8M |
总债务ASPIDCTH
| Q4 25 | $14.4M | — | ||
| Q3 25 | $13.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $2.0M | ||
| Q2 24 | — | $4.5M | ||
| Q1 24 | — | $7.4M |
股东权益ASPIDCTH
| Q4 25 | $204.2M | $111.2M | ||
| Q3 25 | $74.1M | $114.8M | ||
| Q2 25 | — | $105.0M | ||
| Q1 25 | — | $80.2M | ||
| Q4 24 | — | $68.7M | ||
| Q3 24 | — | $8.6M | ||
| Q2 24 | — | $4.2M | ||
| Q1 24 | — | $14.6M |
总资产ASPIDCTH
| Q4 25 | $498.0M | $123.6M | ||
| Q3 25 | $225.9M | $124.3M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $87.3M | ||
| Q4 24 | — | $76.6M | ||
| Q3 24 | — | $31.7M | ||
| Q2 24 | — | $33.9M | ||
| Q1 24 | — | $36.1M |
负债/权益比ASPIDCTH
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 1.07× | ||
| Q1 24 | — | 0.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-37.8M | $8.2M |
| 自由现金流经营现金流 - 资本支出 | $-47.4M | $7.7M |
| 自由现金流率自由现金流/营收 | -284.7% | 37.1% |
| 资本支出强度资本支出/营收 | 57.9% | 2.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $21.0M |
8季度趋势，按日历期对齐
经营现金流ASPIDCTH
| Q4 25 | $-37.8M | $8.2M | ||
| Q3 25 | $-8.9M | $4.8M | ||
| Q2 25 | — | $7.3M | ||
| Q1 25 | — | $2.2M | ||
| Q4 24 | — | $-1.0M | ||
| Q3 24 | — | $-3.6M | ||
| Q2 24 | — | $-4.5M | ||
| Q1 24 | — | $-9.6M |
自由现金流ASPIDCTH
| Q4 25 | $-47.4M | $7.7M | ||
| Q3 25 | $-12.0M | $4.3M | ||
| Q2 25 | — | $6.9M | ||
| Q1 25 | — | $2.1M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-3.9M | ||
| Q2 24 | — | $-4.6M | ||
| Q1 24 | — | $-9.6M |
自由现金流率ASPIDCTH
| Q4 25 | -284.7% | 37.1% | ||
| Q3 25 | -245.5% | 21.0% | ||
| Q2 25 | — | 28.5% | ||
| Q1 25 | — | 10.4% | ||
| Q4 24 | — | -8.2% | ||
| Q3 24 | — | -34.4% | ||
| Q2 24 | — | -58.6% | ||
| Q1 24 | — | -305.7% |
资本支出强度ASPIDCTH
| Q4 25 | 57.9% | 2.7% | ||
| Q3 25 | 64.4% | 2.2% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | 1.5% | ||
| Q3 24 | — | 1.9% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | 0.4% |
现金转化率ASPIDCTH
| Q4 25 | — | — | ||
| Q3 25 | — | 5.75× | ||
| Q2 25 | — | 2.70× | ||
| Q1 25 | — | 2.06× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1.95× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASPI
暂无分部数据
DCTH
| HEPZATOKIT | $19.1M | 92% |
| CHEMOSAT | $1.7M | 8% |
